



Drug Name: Arikayce (Amikacin Liposome Inhalation Suspension)

Date: 4/15/19

Drug Name: Arikayce (Amikacin Liposome Inhalation Suspension)	
Required Medical Information:	<ul style="list-style-type: none">• Patient has diagnosis of refractory <i>Mycobacterium avium</i> complex (MAC) lung disease and has not achieved negative sputum culture after minimum of 6 months of multidrug background regimen therapy.
Coverage duration:	6 months